Form 4 for ACRS Aclaris Therapeutics, Inc.
Accepted 2025-12-04 00:00:00 ET · period of report 2025-12-02 · accession 0002045027-25-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-04 | 2025-12-02 | ACRS | Davis Hugh M. | Pres, COO, Dir | M - OptEx | — | +26.8K | 26.8K | New | — |
| D | 2025-12-04 | 2025-12-02 | ACRS | Davis Hugh M. | Pres, COO, Dir | M - OptEx | $0.00 | -26.8K | 80.2K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-02 | M | A | 26,750 | — | 26,750 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. |
| 2 | Derivative | Restricted Stock Units | 2025-12-02 | M | D | 26,750 | $0.00 | 80,250 | D | — · — to — | 26,750 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. (F2) The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of December 2, 2024 (in each case rounded down to the nearest whole share, except for the last vesting installment), subject to the Continuous Service (as defined in the Issuer's 2024 Inducement Plan) of the Reporting Person as of each such date. |